logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Half of melanoma patients in pivotal nivolumab+ipilimumab trial are still alive after 5 years

This 5-year analysis represents the longest phase 3 follow-up for any checkpoint inhibitor combination therapy.